Why do sglt2 inhibitors cause ketoacidosis

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: SGLT2 inhibitors cause ketoacidosis primarily by promoting ketone body production while simultaneously reducing insulin secretion and increasing glucagon levels. This creates a state of euglycemic ketoacidosis where blood glucose levels may appear normal (typically 90-250 mg/dL) despite dangerous ketone accumulation. The risk is highest during illness, surgery, or reduced carbohydrate intake, with incidence rates ranging from 0.1% to 0.8% in clinical trials. The FDA issued a safety warning about this risk in May 2015.

Key Facts

SGLT2 inhibitors increase glucagon-to-insulin ratio by 20-30%
Euglycemic ketoacidosis typically occurs with blood glucose <250 mg/dL
FDA issued safety warning in May 2015
Risk increases 7-fold during illness or surgery
Ketone levels can exceed 3.0 mmol/L in severe cases

Overview

SGLT2 inhibitors, first approved by the FDA in 2013 for type 2 diabetes, work by blocking sodium-glucose cotransporter 2 in the kidneys to promote glucose excretion. These medications include canagliflozin, dapagliflozin, and empagliflozin. While effective for glycemic control and cardiovascular benefits, they carry a unique risk of euglycemic diabetic ketoacidosis (euDKA), where patients develop dangerous ketone accumulation despite normal or only mildly elevated blood glucose levels. This paradoxical effect was first systematically reported in 2015, leading to regulatory warnings. Unlike traditional diabetic ketoacidosis that typically occurs with blood glucose >250 mg/dL, euDKA often presents with glucose levels between 90-250 mg/dL, making diagnosis challenging. The condition affects approximately 0.1-0.8% of users, with higher rates in type 1 diabetes off-label use.

How It Works

SGLT2 inhibitors trigger ketoacidosis through multiple interconnected mechanisms. First, by increasing urinary glucose excretion (typically 60-100 grams daily), they reduce circulating glucose levels, which signals the body to switch to fat metabolism. Second, they directly stimulate glucagon secretion from pancreatic alpha cells while suppressing insulin secretion from beta cells, creating a hormonal environment favoring ketogenesis. Third, the medications enhance lipolysis in adipose tissue, releasing free fatty acids that the liver converts to ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). Normally, insulin would inhibit this process, but with reduced insulin signaling, ketone production proceeds unchecked. Finally, SGLT2 inhibitors may reduce renal clearance of ketones, allowing accumulation. This perfect storm occurs most frequently during physiological stress like infection, surgery, or reduced carbohydrate intake.

Why It Matters

Understanding SGLT2 inhibitor-induced ketoacidosis is crucial because delayed diagnosis can lead to severe complications including cerebral edema, cardiac arrhythmias, and death. The euglycemic presentation means traditional warning signs (very high blood sugar) are absent, potentially delaying treatment by 24-72 hours. Patients and healthcare providers must recognize early symptoms like nausea, vomiting, abdominal pain, and fatigue, and check ketone levels even with normal glucose readings. This knowledge has changed clinical practice, with guidelines now recommending temporary discontinuation before surgery, during illness, or when carbohydrate intake is reduced. The phenomenon also provides insights into metabolic regulation, demonstrating how subtle hormonal shifts can dramatically alter fuel metabolism.